CN101311160A - 一种丹参丹酚酸a的制备方法 - Google Patents
一种丹参丹酚酸a的制备方法 Download PDFInfo
- Publication number
- CN101311160A CN101311160A CNA2007100996188A CN200710099618A CN101311160A CN 101311160 A CN101311160 A CN 101311160A CN A2007100996188 A CNA2007100996188 A CN A2007100996188A CN 200710099618 A CN200710099618 A CN 200710099618A CN 101311160 A CN101311160 A CN 101311160A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- danshen root
- root salvianolic
- hpd
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 240000007164 Salvia officinalis Species 0.000 title description 12
- 235000005412 red sage Nutrition 0.000 title description 11
- 239000002253 acid Substances 0.000 title description 6
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 claims abstract description 111
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 claims abstract description 111
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims abstract description 51
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims abstract description 51
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims abstract description 51
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 47
- 238000002360 preparation method Methods 0.000 claims abstract description 36
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 244000132619 red sage Species 0.000 claims description 124
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 239000000284 extract Substances 0.000 claims description 46
- 239000000706 filtrate Substances 0.000 claims description 32
- 239000012141 concentrate Substances 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 26
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 24
- 238000012546 transfer Methods 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- 238000013375 chromatographic separation Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 3
- 229940043232 butyl acetate Drugs 0.000 claims description 3
- 229940093499 ethyl acetate Drugs 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 3
- 229940090181 propyl acetate Drugs 0.000 claims description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 16
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 4
- 238000002474 experimental method Methods 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- -1 efficient part Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000003672 processing method Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 238000000638 solvent extraction Methods 0.000 description 6
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000415078 Anemone hepatica Species 0.000 description 3
- 101800004637 Communis Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 108700004675 bleomycetin Proteins 0.000 description 3
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008899 fufang danshen Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000007965 phenolic acids Chemical group 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical group C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100203936 Mus musculus Srpra gene Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical group CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100996188A CN101311160B (zh) | 2007-05-25 | 2007-05-25 | 一种丹参丹酚酸a的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100996188A CN101311160B (zh) | 2007-05-25 | 2007-05-25 | 一种丹参丹酚酸a的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101311160A true CN101311160A (zh) | 2008-11-26 |
CN101311160B CN101311160B (zh) | 2012-04-11 |
Family
ID=40100011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100996188A Expired - Fee Related CN101311160B (zh) | 2007-05-25 | 2007-05-25 | 一种丹参丹酚酸a的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101311160B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991565A (zh) * | 2010-12-13 | 2011-03-30 | 南京中医药大学 | 丹酚酸a在制备诱导肿瘤细胞凋亡和/或抑制肿瘤细胞增殖药物中的应用 |
CN102028678A (zh) * | 2010-12-13 | 2011-04-27 | 南京中医药大学 | 丹酚酸a在制备抗肿瘤转移药物中的应用 |
CN102212004A (zh) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | 一种催化转化丹酚酸b制备丹酚酸a的方法 |
CN102212005A (zh) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | 一种采用正相色谱法纯化丹参酚酸a的方法 |
CN102219685A (zh) * | 2010-04-16 | 2011-10-19 | 北京本草天源药物研究院 | 一种丹参丹酚酸a的制备方法 |
CN102531901A (zh) * | 2010-12-25 | 2012-07-04 | 上海绿谷制药有限公司 | 一种丹酚酸a的制备方法 |
CN102557940A (zh) * | 2010-12-10 | 2012-07-11 | 北京本草天源药物研究院 | 一种丹参丹酚酸a的制备方法 |
CN102827002A (zh) * | 2012-05-29 | 2012-12-19 | 北京正大绿洲医药科技有限公司 | 一种丹参酚酸a的化学全合成方法 |
CN103044252A (zh) * | 2012-11-20 | 2013-04-17 | 陆文萍 | 一种丹酚酸a制备方法 |
CN103242161A (zh) * | 2013-05-17 | 2013-08-14 | 成都科源生物技术有限公司 | 一种制备丹酚酸a的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1110139A (zh) * | 1994-04-15 | 1995-10-18 | 中国医学科学院医药生物技术研究所 | 丹酚酸a用于***新用途 |
CN1397276A (zh) * | 2002-08-07 | 2003-02-19 | 沈阳药科大学 | 中药丹参中sla-a及其组合物的制备方法和医药用途 |
-
2007
- 2007-05-25 CN CN2007100996188A patent/CN101311160B/zh not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102212004B (zh) * | 2010-04-06 | 2014-04-09 | 苏州雷纳药物研发有限公司 | 一种催化转化丹酚酸b制备丹酚酸a的方法 |
CN102212004A (zh) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | 一种催化转化丹酚酸b制备丹酚酸a的方法 |
CN102212005A (zh) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | 一种采用正相色谱法纯化丹参酚酸a的方法 |
CN102219685B (zh) * | 2010-04-16 | 2015-11-11 | 北京本草天源药物研究院 | 一种丹参丹酚酸a的制备方法 |
CN102219685A (zh) * | 2010-04-16 | 2011-10-19 | 北京本草天源药物研究院 | 一种丹参丹酚酸a的制备方法 |
CN102557940A (zh) * | 2010-12-10 | 2012-07-11 | 北京本草天源药物研究院 | 一种丹参丹酚酸a的制备方法 |
CN101991565A (zh) * | 2010-12-13 | 2011-03-30 | 南京中医药大学 | 丹酚酸a在制备诱导肿瘤细胞凋亡和/或抑制肿瘤细胞增殖药物中的应用 |
CN102028678A (zh) * | 2010-12-13 | 2011-04-27 | 南京中医药大学 | 丹酚酸a在制备抗肿瘤转移药物中的应用 |
CN102531901A (zh) * | 2010-12-25 | 2012-07-04 | 上海绿谷制药有限公司 | 一种丹酚酸a的制备方法 |
CN102531901B (zh) * | 2010-12-25 | 2015-04-08 | 苏州雷纳药物研发有限公司 | 一种丹酚酸a的制备方法 |
CN102827002A (zh) * | 2012-05-29 | 2012-12-19 | 北京正大绿洲医药科技有限公司 | 一种丹参酚酸a的化学全合成方法 |
CN103044252A (zh) * | 2012-11-20 | 2013-04-17 | 陆文萍 | 一种丹酚酸a制备方法 |
CN103044252B (zh) * | 2012-11-20 | 2015-08-26 | 江西青峰药业有限公司 | 一种丹酚酸a制备方法 |
CN103242161A (zh) * | 2013-05-17 | 2013-08-14 | 成都科源生物技术有限公司 | 一种制备丹酚酸a的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101311160B (zh) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101311160B (zh) | 一种丹参丹酚酸a的制备方法 | |
CN100999470B (zh) | 一种丹参丹酚酸a及制剂 | |
CN101230003B (zh) | 一种丹参丹酚酸a的制备方法 | |
CN100569219C (zh) | 一种用于口服制剂的药物组合物及其制备方法 | |
JP6133415B2 (ja) | 水酸基ベニバナ黄色素aナトリウムの製造方法及び用途 | |
CN1762967B (zh) | 甘草次酸衍生物、制备方法及其用途 | |
CN101033245B (zh) | 具栖冬青苷的制备方法及应用 | |
CN1931236B (zh) | 一种由丹参和红景天制成的药物组合物 | |
CN101278939B (zh) | 治疗心脑血管疾病的药物组合物及其制备方法 | |
WO2018133563A1 (zh) | 一种人参属植物提取物及其药物组合物和应用 | |
CN101759672B (zh) | 丹参丹酚酸b | |
CN104435034A (zh) | 一种三七总皂苷及其制备方法 | |
CN101006984B (zh) | 一种丹参丹酚酸a、三七提取物的注射制剂及其制备方法和应用 | |
CN101696166B (zh) | 一种丹参丹酚酸a的制备方法 | |
CN101283999A (zh) | 一种主要用于治疗心脑血管疾病的药物组合物及其制备方法 | |
CN101006975B (zh) | 一种丹参丹酚酸a、三七提取物的口服制剂及其制备方法和应用 | |
CN1994277B (zh) | 一种丹参丹酚酸a固体制剂及其制备方法 | |
CN100467025C (zh) | 积雪草总苷、积雪草苷或羟基积雪草苷在制备防治心、脑血管疾病药物中的用途 | |
CN101293009A (zh) | 药物组合物 | |
CN107334813A (zh) | 一种四方蒿提取物及其制法和用途 | |
CN102266386B (zh) | 一种黄芩提取物及其制备方法和用途 | |
CN101269062B (zh) | 马钱素在制备治疗心脑血管疾病的药物中的应用 | |
CN100496481C (zh) | 一种治疗心脑血管疾病的药物组合物及其制备方法 | |
CN101176751B (zh) | 丹参和桂枝的药物组合物 | |
CN101759751A (zh) | 含有杂质人参皂苷Re的人参皂苷Rg1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification of Termination of Patent Right |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification of Decision on Request for Restoration of Right |
|
DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification of Termination of Patent Right |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120411 Termination date: 20180525 |
|
CF01 | Termination of patent right due to non-payment of annual fee |